<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLOWTUSS- guaifenesin and hydrocodone bitartrate liquid </strong><br>Mission Pharmacal Company<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use FLOWTUSS™ safely and effectively. See full prescribing information for FLOWTUSS.
  <br><br>
FLOWTUSS (hydrocodone bitartrate and guaifenesin) oral solution, CII
  <br><br>
Initial U.S. Approval: 2014
 </span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">FLOWTUSS is a combination of hydrocodone, an opioid antitussive, and guaifenesin, an expectorant indicated for the symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and to loosen mucus associated with the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.
    <br>  (<a href="#section-1">1</a>)</p>
<p class="Highlighta"><span class="Underline">Important Limitations of Use:</span><br>
Not indicated for pediatric patients under 18 years of age (8.4)
     (<a href="#section-1">1</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">• Adults and adolescents 18 years of age and older: 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours (2.1)
    <br>
• Measure FLOWTUSS with an accurate milliliter measuring device. (5.9)
     (<a href="#section-2">2</a>)</p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Oral solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg. (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">• Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, guaifenesin, or any of the inactive ingredients of FLOWTUSS. (4)
    <br>
• Patients receiving monoamine oxidase inhibitor (MAOI) therapy or within 14 days of stopping such therapy. (4)
     (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">• Dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>: Use with caution. (5.1)
    <br>
• <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span>: Prescribe with caution that is appropriate to the use of other opioids. (5.2)
    <br>
• <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>: Avoid in patients with <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, intracranial lesions or <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span>. (5.3)
     (<a href="#section-5">5</a>)</p>
<p class="Highlighta">• Activities requiring mental alertness: Avoid engaging in hazardous tasks requiring complete mental alertness such as driving or operating machinery. (5.4)
    <br>
• Acute abdominal conditions: Use with caution in patients with acute abdominal conditions. (5.5)
    <br>
• Coexisting conditions: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>, or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (5.10)
     (<a href="#section-5">5</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions of FLOWTUSS include: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and decreased blood pressure (6)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta">  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mission Pharmacal Company at 1-800-298-1087 or FDA at 1-800-FDA-1088 or 
     <span class="Italics">www.fda.gov/medwatch</span>.
    </span>  (<a href="#section-6">6</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">• Opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants (including alcohol): Avoid using with FLOWTUSS; may exhibit additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. (7.1)
    <br>
• MAO inhibitors (MAOIs) or tricyclic antidepressants: Do not use. May increase the effect of either the antidepressant or hydrocodone. (7.2)
    <br>
• Anticholinergic drugs: Use with caution in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects. (7.3)
     (<a href="#section-7">7</a>)</p></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">• <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (8.6)
    <br>
• <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (8.7)
     (<a href="#section-8">8</a>)</p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-2" class="toc"><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1 Recommended Dosage</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4 CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4 Activities Requiring Mental Alertness</span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5 Acute Abdominal Conditions</span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 Co-administration with Anticholinergics</span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.7 Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.8 Persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9 Dosing</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.10 Coexisting Conditions</span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-5.12" class="toc"><span class="Bold">5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6 ADVERSE REACTIONS</span></a></h1>
<h1><a href="#section-7" class="toc"><span class="Bold">7 DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2 MAO Inhibitors or Tricyclic Antidepressants</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.3 Anticholinergic Drugs</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1 Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2 Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3 Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4 Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5 Geriatric Use</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="Bold">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></a></h1>
<h2><a href="#section-9.1" class="toc"><span class="Bold">9.1 Controlled Substance</span></a></h2>
<h2><a href="#section-9.2" class="toc"><span class="Bold">9.2 Abuse</span></a></h2>
<h2><a href="#section-9.3" class="toc"><span class="Bold">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span></a></h2>
<h1><a href="#section-10" class="toc"><span class="Bold">10 OVERDOSAGE</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">11 DESCRIPTION</span></a></h1>
<h1><a href="#section-12" class="toc"><span class="Bold">12 CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">12.1 Mechanism of Action</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">12.3 Pharmacokinetics</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">14 CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="id_link_1d0cdc40-018b-5683-e054-00144ff88e88"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">1 INDICATIONS AND USAGE</span></h1>
<p class="First">FLOWTUSS is indicated for symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and to loosen mucus associated with the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>.
  <br></p>
<p><span class="Underline">Important Limitations of Use:</span><br>
Not indicated for pediatric patients under 18 years of age [
  <span class="Italics">see Use in Specific Populations (8.4)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="id_link_1d0cdc40-018d-5683-e054-00144ff88e88"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">2 DOSAGE AND ADMINISTRATION</span></h1>
<div class="Section" data-sectionCode="34068-7">
<a name="id_link_1d0cdc40-01a7-5683-e054-00144ff88e88"></a><a name="section-2.1"></a><p></p>
<h2><span class="Bold">2.1 Recommended Dosage</span></h2>
<p class="First"><span class="Underline">Adults and adolescents 18 years of age and older:</span> 10 mL every 4 to 6 hours, not to exceed 6 doses (60 mL) in 24 hours.
 </p>
<p></p>
<p>Administer FLOWTUSS by the oral route only. Measure FLOWTUSS with an accurate milliliter measuring device. Do not use a household teaspoon to measure the dose [
  <span class="Italics">see Warnings and Precautions (5.9)</span>].
 </p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="id_link_1d0c0009-7284-4c54-e054-00144ff8d46c"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">3 DOSAGE FORMS AND STRENGTHS</span></h1>
<p class="First">Oral solution: Each 5 mL contains hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg [
  <span class="Italics">see Description (11)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="id_link_1d0c0009-7286-4c54-e054-00144ff8d46c"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">4 CONTRAINDICATIONS</span></h1>
<p class="First">FLOWTUSS is contraindicated in:
  <br>
• Patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrocodone bitartrate, guaifenesin, or any of the inactive ingredients of FLOWTUSS.
  <br>
• Patients receiving MAOI therapy or within 14 days of stopping such therapy [
  <span class="Italics">see Drug Interactions (7.2)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-7289-4c54-e054-00144ff8d46c"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">5 WARNINGS AND PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-728b-4c54-e054-00144ff8d46c"></a><a name="section-5.1"></a><p></p>
<h2><span class="Bold">5.1 <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></span></h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in FLOWTUSS, produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of hydrocodone bitartrate in adults has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and the use of hydrocodone bitartrate in children less than 6 years of age has been associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Exercise caution when administering FLOWTUSS because of the potential for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated [
  <span class="Italics">see Overdosage (10)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-728d-4c54-e054-00144ff8d46c"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">5.2 <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></span></h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of FLOWTUSS. Prescribe and administer FLOWTUSS with the same degree of caution appropriate to the use of other opioid drugs [
  <span class="Italics">see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.2), (9.3)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-728f-4c54-e054-00144ff8d46c"></a><a name="section-5.3"></a><p></p>
<h2><span class="Bold">5.3 <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></span></h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> effects of opioids and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, opioids produce adverse reactions which may obscure the clinical course of patients with head injuries. The use of FLOWTUSS should be avoided in these patients.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d1ff1-e4ad-6043-e054-00144ff88e88"></a><a name="section-5.4"></a><p></p>
<h2><span class="Bold">5.4 Activities Requiring Mental Alertness</span></h2>
<p class="First">Hydrocodone bitartrate, one of the active ingredients in FLOWTUSS, may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Advise patients to avoid engaging in hazardous tasks requiring mental alertness and motor coordination after ingestion of FLOWTUSS. Concurrent use of FLOWTUSS with alcohol or other central nervous system depressants should be avoided because additional impairment of central nervous system performance may occur.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d1ff1-e4af-6043-e054-00144ff88e88"></a><a name="section-5.5"></a><p></p>
<h2><span class="Bold">5.5 Acute Abdominal Conditions</span></h2>
<p class="First">FLOWTUSS should be used with caution in patients with acute abdominal conditions since the administration of hydrocodone may obscure the diagnosis or clinical course of patients with acute abdominal conditions. The concurrent use of other anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> [
  <span class="Italics">see Drug Interactions (7.3)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d1ff1-e4b1-6043-e054-00144ff88e88"></a><a name="section-5.6"></a><p></p>
<h2><span class="Bold">5.6 Co-administration with Anticholinergics</span></h2>
<p class="First">The concurrent use of anticholinergics with hydrocodone may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>. Exercise caution when using FLOWTUSS in patients taking anticholinergic medications [
  <span class="Italics">see Drug Interactions (7.3)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-7293-4c54-e054-00144ff8d46c"></a><a name="section-5.7"></a><p></p>
<h2><span class="Bold">5.7 Co-administration with Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants</span></h2>
<p class="First">FLOWTUSS should not be used in patients receiving monoamine oxidase inhibitors (MAOI) therapy or within 14 days of stopping such therapy. The use of MAOIs or tricyclic antidepressants with hydrocodone bitartrate may increase the effect of either the antidepressant or hydrocodone [
  <span class="Italics">see Contraindications (4) and Drug Interactions (7.2)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0c0009-7295-4c54-e054-00144ff8d46c"></a><a name="section-5.8"></a><p></p>
<h2><span class="Bold">5.8 Persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></h2>
<p class="First">FLOWTUSS should not be used in patients with a persistent or <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">chronic cough</span> such as occurs with smoking, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, or <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, or where <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> is accompanied by excessive <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">phlegm</span> (mucus).</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d52fd-7437-65f3-e054-00144ff8d46c"></a><a name="section-5.9"></a><p></p>
<h2><span class="Bold">5.9 Dosing</span></h2>
<p class="First">Patients should be advised to measure FLOWTUSS with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, which can result in serious adverse reactions [
  <span class="Italics">see Overdosage (10)</span>]. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose.
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d1ff1-e4b6-6043-e054-00144ff88e88"></a><a name="section-5.10"></a><p></p>
<h2><span class="Bold">5.10 Coexisting Conditions</span></h2>
<p class="First">FLOWTUSS should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, thyroid disease, Addison’s disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d52fd-7439-65f3-e054-00144ff8d46c"></a><a name="section-5.11"></a><p></p>
<h2><span class="Bold">5.11 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">FLOWTUSS should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [
  <span class="Italics">see Use in Specific Populations (8.6)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="id_link_1d0d52fd-743b-65f3-e054-00144ff8d46c"></a><a name="section-5.12"></a><p></p>
<h2><span class="Bold">5.12 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">FLOWTUSS should be used with caution in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [
  <span class="Italics">see Use in Specific Populations (8.7)</span>].
 </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="id_link_1d0d52fd-743d-65f3-e054-00144ff8d46c"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">6 ADVERSE REACTIONS</span></h1>
<p class="First">Use of hydrocodone bitartrate is associated with the following:
  <br>
• <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> [
  <span class="Italics">see Warnings and Precautions (5.1) and Overdosage (10)</span>]
  <br>
• <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span> [
  <span class="Italics">see Warnings and Precautions (5.2) and Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (9.3)</span>]
  <br>
• <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> [
  <span class="Italics">see Warnings and Precautions (5.3)</span>]
  <br>
• Decreased mental alertness with impaired mental and/or physical abilities [
  <span class="Italics">see Warnings and Precautions (5.4)</span>]
  <br>
• <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span> [
  <span class="Italics">see Warnings and Precautions (5.5)</span>]
 </p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p></p>
<p>The most common adverse reactions experienced by subjects taking a single dose of FLOWTUSS in the clinical setting include the following: Central Nervous System: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, sedation (<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>); Gastrointestinal System: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; Cardiovascular System: decreased blood pressure; Vascular System: <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="id_link_1d0d52fd-743f-65f3-e054-00144ff8d46c"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">7 DRUG INTERACTIONS</span></h1>
<p class="First">No specific interaction studies have been conducted with FLOWTUSS.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="id_link_1d0d1ff1-e4b8-6043-e054-00144ff88e88"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">7.1 Opioids, Antihistamines, Antipsychotics, Anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> Agents, or Other CNS Depressants (Including Alcohol)</span></h2>
<p class="First">The use of opioids, antihistamines, antipsychotics, anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> agents, or other CNS depressants concomitantly with FLOWTUSS may cause an additive CNS depressant effect and should be avoided.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="id_link_1d0d52fd-7442-65f3-e054-00144ff8d46c"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">7.2 MAO Inhibitors or Tricyclic Antidepressants</span></h2>
<p class="First">Do not prescribe FLOWTUSS if the patient is taking a prescription MAOI (i.e., certain drugs used for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping a MAOI drug. The use of MAOIs or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone [
  <span class="Italics">see Warnings and Precautions (5.7)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="id_link_1d0d52fd-7445-65f3-e054-00144ff8d46c"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">7.3 Anticholinergic Drugs</span></h2>
<p class="First">Hydrocodone should be administered cautiously to persons receiving anticholinergic drugs in order to avoid <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and excessive anticholinergic effects [
  <span class="Italics">see Warnings and Precautions (5.6)</span>].
 </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4bd-6043-e054-00144ff88e88"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">8 USE IN SPECIFIC POPULATIONS</span></h1>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4ec-6043-e054-00144ff88e88"></a><a name="section-8.1"></a><p></p>
<h2><span class="Bold">8.1 Pregnancy</span></h2>
<p class="First"><span class="Underline">Teratogenic Effects</span><br><span class="Italics">Pregnancy Category C</span><br>
There are no adequate and well controlled studies of FLOWTUSS in pregnant women. Reproductive toxicity studies have not been conducted with FLOWTUSS; however, studies are available with an individual active ingredient or related active ingredient. Hydrocodone was teratogenic in hamsters. Codeine, an opiate related to hydrocodone, increased resorptions and decreased fetal weight in rats. Because animal reproduction studies are not always predictive of human response, FLOWTUSS should be used during pregnancy only if the benefit justifies the potential risk to the fetus.
 </p>
<p></p>
<p><span class="Italics">Hydrocodone</span><br>
Hydrocodone has been shown to be teratogenic in hamsters when given in a dose approximately 27 times the maximum recommended human daily dose (MRHDD) (on a mg/m
  <span class="Sup">2</span> basis at a single subcutaneous dose of 102 mg/kg on gestation day 8). Reproductive toxicology studies were also conducted with codeine, an opiate related to hydrocodone. In a study in which pregnant rats were dosed throughout organogenesis, a dose of codeine approximately 40 times the MRHDD of hydrocodone (on a mg/m
  <span class="Sup">2</span> basis at an oral dose of 120 mg/kg/day of codeine) increased resorptions and decreased fetal weight; however, these effects occurred in the presence of maternal toxicity. In studies in which rabbits and mice were dosed throughout organogenesis, doses of codeine up to approximately 20 and 100 times, respectively, the MRHDD of hydrocodone (on a mg/m
  <span class="Sup">2</span> basis at oral doses of 30 and 600 mg/kg/day, respectively), produced no adverse developmental effects.
 </p>
<p></p>
<p><span class="Underline">Non-teratogenic Effects</span><br>
Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
 </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4ee-6043-e054-00144ff88e88"></a><a name="section-8.2"></a><p></p>
<h2><span class="Bold">8.2 Labor and Delivery</span></h2>
<p class="First">As with all opioids, administration of FLOWTUSS to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4f0-6043-e054-00144ff88e88"></a><a name="section-8.3"></a><p></p>
<h2><span class="Bold">8.3 Nursing Mothers</span></h2>
<p class="First">Caution should be exercised when FLOWTUSS is administered to nursing mothers. Hydrocodone is known to be excreted in human milk. No studies have been performed to determine if guaifenesin is excreted into breastmilk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from FLOWTUSS, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4f2-6043-e054-00144ff88e88"></a><a name="section-8.4"></a><p></p>
<h2><span class="Bold">8.4 Pediatric Use</span></h2>
<p class="First">Safety and effectiveness of FLOWTUSS in pediatric patients under 18 years of age has not been established. The use of hydrocodone in children less than 6 years of age is associated with fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> [
  <span class="Italics">see Warnings and Precautions (5.1)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4f4-6043-e054-00144ff88e88"></a><a name="section-8.5"></a><p></p>
<h2><span class="Bold">8.5 Geriatric Use</span></h2>
<p class="First">Clinical studies have not been conducted with FLOWTUSS in geriatric populations. Other reported clinical experience with the individual active ingredients of FLOWTUSS has not identified differences in responses between the elderly and patients younger than 65 years of age. In general, dose selection for an elderly patient should be made with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4f6-6043-e054-00144ff88e88"></a><a name="section-8.6"></a><p></p>
<h2><span class="Bold">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h2>
<p class="First">FLOWTUSS should be given with caution in patients with severe impairment of renal function.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="id_link_1d0d1ff1-e4f8-6043-e054-00144ff88e88"></a><a name="section-8.7"></a><p></p>
<h2><span class="Bold">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h2>
<p class="First">FLOWTUSS should be given with caution in patients with severe impairment of hepatic function.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="id_link_1d0d1ff1-e4fa-6043-e054-00144ff88e88"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<div class="Section" data-sectionCode="42227-9">
<a name="id_link_1d0d52fd-7447-65f3-e054-00144ff8d46c"></a><a name="section-9.1"></a><p></p>
<h2><span class="Bold">9.1 Controlled Substance</span></h2>
<p class="First">FLOWTUSS is a Schedule II controlled prescription containing hydrocodone bitartrate and should be prescribed and administered with caution.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="id_link_1d0db584-f1cf-6f0a-e054-00144ff88e88"></a><a name="section-9.2"></a><p></p>
<h2><span class="Bold">9.2 Abuse</span></h2>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of FLOWTUSS, and it should be prescribed and administered with the same degree of caution appropriate to the use of other opioid drugs.</p>
<p>Abuse of guaifenesin has been linked to the formation of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> composed of the major metabolite β-(2-methoxyphenoxy) lactic acid.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="id_link_1d0d52fd-7449-65f3-e054-00144ff8d46c"></a><a name="section-9.3"></a><p></p>
<h2><span class="Bold">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></span></h2>
<p class="First">Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, and tolerance may develop upon repeated administration of opioids; therefore, FLOWTUSS should be prescribed and administered with caution [
  <span class="Italics">see Warnings and Precautions (5.2)</span>].
 </p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral opioid use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of opioid therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="id_link_1d0dbe52-7146-73f1-e054-00144ff88e88"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">10 OVERDOSAGE</span></h1>
<p class="First">No human overdosage data are available for FLOWTUSS.</p>
<p></p>
<p><span class="Underline">Hydrocodone</span><br>
Overdosage with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, ringing in the ears, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, eye problems, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.
 </p>
<p></p>
<p><span class="Underline">Guaifenesin</span><br>
Overdosage with guaifenesin can cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system. While present in polypharmacy <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with only significant levels of guaifenesin has been reported. Symptoms included <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, shallow respirations, reduced heart rate with rhythm <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, followed by <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">asystole</span>.
 </p>
<p></p>
<p>Treatment of overdosage consists of discontinuation of FLOWTUSS together with institution of appropriate therapy. Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The opioid antagonist naloxone hydrochloride is a specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to opioids including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="id_link_1d0d52fd-7451-65f3-e054-00144ff8d46c"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">11 DESCRIPTION</span></h1>
<p class="First">FLOWTUSS (hydrocodone bitartrate and guaifenesin) oral solution contains hydrocodone bitartrate (a centrally-acting opioid antitussive) and guaifenesin (an expectorant).</p>
<p></p>
<p>Each 5 mL dose of FLOWTUSS contains: hydrocodone bitartrate, USP, 2.5 mg; and guaifenesin, USP, 200 mg.</p>
<p></p>
<p>FLOWTUSS also contains: black raspberry flavor, citric acid, D&amp;C Red #33, FD&amp;C Blue #1, glycerin, methylparaben, polyethylene glycol, propylparaben, purified water, saccharin sodium, sodium citrate, and sorbitol.</p>
<p></p>
<p><span class="Underline">Hydrocodone Bitartrate</span><br>
Hydrocodone bitartrate is a centrally-acting opioid antitussive and analgesic. It is affected by light and occurs as fine white crystals or crystalline powder which is derived from the opium alkaloid, thebaine. Its chemical name is morphinan-6-one, 4,5-epoxy-3-methoxy- 17-methyl-, (5α)-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1), hydrate (2:5). It is also known as 4,5α-Epoxy-3-methoxy-17-methylmorphinan-6-one tartrate (1:1) hydrate (2:5); and may be represented by the following structural formula:
 </p>
<p><img alt="structure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d0c2c03-ca11-30b1-e054-00144ff8d46c&amp;name=structure1.jpg"></p>
<p><span class="Underline">Guaifenesin</span><br>
Guaifenesin is an expectorant and occurs as a white powder. Its chemical name is 3-(2-methoxyphenoxy)-1,2-propanediol, and may be represented by the following structural formula:
 </p>
<p><img alt="structure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d0c2c03-ca11-30b1-e054-00144ff8d46c&amp;name=structure2.jpg"></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="id_link_1d0e6f4b-b950-078e-e054-00144ff8d46c"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">12 CLINICAL PHARMACOLOGY</span></h1>
<div class="Section" data-sectionCode="34090-1">
<a name="id_link_1d0e6f4b-b952-078e-e054-00144ff8d46c"></a><a name="section-12.1"></a><p></p>
<h2><span class="Bold">12.1 Mechanism of Action</span></h2>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone will depress respiration. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, and physical and physiological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p></p>
<p>Guaifenesin is an expectorant the action of which promotes or facilitates the removal of secretions from the respiratory tract. The precise mechanism of action of guaifenesin is not known; however, it is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi. In turn, this may increase the efficiency of the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex and facilitate removal of the secretions.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="id_link_1d0e84a1-24ce-165b-e054-00144ff88e88"></a><a name="section-12.2"></a><p></p>
<h2><span class="Bold">12.3 Pharmacokinetics</span></h2>
<p class="First">Systemic exposure (in terms of peak plasma concentrations and area under plasma concentration versus time curve) of hydrocodone bitartrate and guaifenesin after a single 10 mL oral dose administration of 5 mg hydrocodone bitartrate and 400 mg guaifenesin are equivalent to the respective reference solutions of 5 mL hydrocodone bitartrate (5 mg/5 mL), and 10 mL guaifenesin (200 mg/5 mL).</p>
<p></p>
<p><span class="Underline">Hydrocodone</span><br>
Following a single 10 mL oral dose of 5 mg hydrocodone bitartrate and 400 mg guaifenesin administered to 37 healthy adults, the geometric mean C
  <span class="Sub">max</span> and AUC
  <span class="Sub">0-inf</span> for hydrocodone were 9.0 ng/mL and 61.2 ng·hr/mL, respectively. The median time to maximum concentration for hydrocodone was about 1.67 hours. Food has no significant effect on the extent of absorption of hydrocodone. The mean plasma half-life of hydrocodone is approximately 4 hours.
 </p>
<p></p>
<p><span class="Underline">Guaifenesin</span><br>
Following a single 10 mL oral dose of 5 mg hydrocodone bitartrate and 400 mg guaifenesin administered to 36 healthy adults, the geometric mean C
  <span class="Sub">max</span> and AUC
  <span class="Sub">0-inf</span> for guaifenesin were 2.0 mcg/mL and 2.6 mcg·hr/mL, respectively. The median time to maximum concentration was about 25 minutes. The effect of food on guaifenesin systemic exposure is not considered to be clinically meaningful. The mean plasma half-life of guaifenesin is approximately 1 hour.
 </p>
<p></p>
<p><span class="Underline">Drug interactions</span><br>
When guaifenesin and hydrocodone were administered in combination, the pharmacokinetics for each component was similar to those observed when each component was administered separately.
 </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="id_link_1d0dbe52-714a-73f1-e054-00144ff88e88"></a><a name="section-13"></a><p></p>
<h1><span class="Bold">13 NONCLINICAL TOXICOLOGY</span></h1>
<div class="Section" data-sectionCode="43680-8">
<a name="id_link_1d0dbe52-714c-73f1-e054-00144ff88e88"></a><a name="section-13.1"></a><p></p>
<h2><span class="Bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with FLOWTUSS; however, published information is available for the individual active ingredients or related active ingredients.</p>
<p></p>
<p><span class="Underline">Hydrocodone</span><br>
Carcinogenicity studies were conducted with codeine, an opiate related to hydrocodone. In 2 year studies in F344/N rats and B6C3F1 mice, codeine showed no evidence of tumorigenicity at dietary doses up to 70 and 400 mg/kg/day, respectively (approximately 23 and 65 times, respectively, the MRHDD of hydrocodone on a mg/m
  <span class="Sup">2</span> basis).
 </p>
<p></p>
<p><span class="Underline">Guaifenesin</span><br>
Carcinogenicity, genotoxicity, or reproductive toxicology studies have not been conducted with guaifenesin.
 </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="id_link_1d0e84a1-24d0-165b-e054-00144ff88e88"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">14 CLINICAL STUDIES</span></h1>
<p class="First">Efficacy studies were not conducted with FLOWTUSS. Efficacy of FLOWTUSS is based on demonstration of bioequivalence to the individual comparator products [
  <span class="Italics">see Clinical Pharmacology (12.3)</span>].
 </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="id_link_1d0dbe52-7150-73f1-e054-00144ff88e88"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">16 HOW SUPPLIED/STORAGE AND HANDLING</span></h1>
<p class="First">FLOWTUSS (hydrocodone bitartrate and guaifenesin) oral solution is supplied as a violet-colored, black raspberry flavored liquid containing 2.5 mg hydrocodone bitartrate
  <br>
and 200 mg guaifenesin in each 5 mL. It is available in:
  <br>
White HDPE bottles of 16 fl. oz. (473 mL): 
  <span class="Bold">NDC</span> 0178-3482-16
  <br>
White HDPE bottles of 4 fl. oz. (118 mL): 
  <span class="Bold">NDC</span> 0178-3482-04
  <br>
Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
  <br>
Dispense in a tight, light-resistant container, as defined in the USP, with a childresistant closure.
 </p>
</div>
<div class="Section" data-sectionCode="68498-5">
<a name="id_link_1d0e84a1-24d2-165b-e054-00144ff88e88"></a><a name="section-16"></a><p></p>
<h1><span class="Bold">17 PATIENT COUNSELING INFORMATION</span></h1>
<p class="First"><span class="Underline">Overdosage</span><br>
Advise patients not to increase the dose or dosing frequency of FLOWTUSS because serious adverse events such as <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may occur with overdosage [
  <span class="Italics">see Warnings and Precautions (5.1) and Overdosage (10)</span>].
 </p>
<p></p>
<p><span class="Underline">Dosing</span></p>
<p>Advise patients to measure FLOWTUSS with an accurate milliliter measuring device. Patients should be informed that a household teaspoon is not an accurate measuring device and could lead to overdosage, especially when half a teaspoon is measured. Patients should be advised to ask their pharmacist to recommend an appropriate measuring device and for instructions for measuring the correct dose [
  <span class="Italics">see Dosage and Administration (2) and Warnings and Precautions (5.9)</span>].
 </p>
<p></p>
<p><span class="Underline">Concomitant Use of Alcohol and Other Central Nervous System Depressants</span></p>
<p>Advise patients to avoid the use of alcohol and other central nervous system depressants while taking FLOWTUSS because additional reduction in mental alertness may occur [
  <span class="Italics">see Warnings and Precautions (5.4)</span>].
 </p>
<p></p>
<p><span class="Underline">Activities Requiring Mental Alertness</span><br>
Advise patients to avoid engaging in hazardous tasks that require mental alertness and motor coordination such as operating machinery or driving a motor vehicle as FLOWTUSS may produce marked <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> [
  <span class="Italics">see Warnings and Precautions (5.4)</span>].
  <br></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug Dependence</span></span><br>
Caution patients that FLOWTUSS contains hydrocodone bitartrate and can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> [
  <span class="Italics">see Warnings and Precautions (5.2)</span>].
 </p>
<p></p>
<p>Manufactured for:
  <br>
MISSION PHARMACAL COMPANY
  <br>
San Antonio, TX 78230 1355
 </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="id_link_1d0e6f4b-b955-078e-e054-00144ff8d46c"></a><a name="section-17"></a><p></p>
<p class="First"><img alt="label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d0c2c03-ca11-30b1-e054-00144ff8d46c&amp;name=label.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLOWTUSS 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate, guaifenesin liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0178-3482</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>GUAIFENESIN</strong> (GUAIFENESIN) </td>
<td class="formItem">GUAIFENESIN</td>
<td class="formItem">200 mg  in 5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">2.5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C RED NO. 33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">purple</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">RASPBERRY (black raspberry) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0178-3482-16</td>
<td class="formItem">473 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022424</td>
<td class="formItem">08/18/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mission Pharmacal Company
							(008117095)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1d97cf66-0cbf-3c11-e054-00144ff88e88</div>
<div>Set id: 1d0c2c03-ca11-30b1-e054-00144ff8d46c</div>
<div>Version: 2</div>
<div>Effective Time: 20150818</div>
</div>
</div> <div class="DistributorName">Mission Pharmacal Company</div></p>
</body></html>
